|Email Newsletters from Pharmaceutical Technology and Pharmaceutical Technology Europe|
Providing the latest business, scientific, and regulatory news for the pharmaceutical and biotech industries.
News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts.
Industry Briefs: October 8, 2012
Accupac has announced that it is doubling its capacity and expanding its manufacturing capabilities with a 221,000-ft2 addition of its facility in Lakewood, New Jersey. Read More
Almac has expanded its MHRA/FDA-approved, United Kingdom commercial-packaging facility with the acquisition of a Noack N 623 blister-packaging line from Romaco. Read More
In other news, Almac and DSM have signed collaboration agreement in biocatalysis to provide manufacturing services to the pharmaceutical industry. Read More
Bend Research and the Dow Chemical Company have formed an exclusive collaboration to provide science-based, spray-dried dispersion solutions and select enabling new polymers for poorly soluble oral drugs. Read More
Dr. Reddy’s has announced an expansion in the areas of activated mPEG manufacturing and in the development and manufacture of APIs for use in preclinical through to commercial development at its manufacturing facility in Mirfield, United Kingdom. Read More
Encap Drug Delivery and the School of Pharmacy, Queen’s University Belfast have received funding from the Technology Strategy Board and the Scottish Government that will allow both to enter into a collaborative Knowledge Transfer Partnership on hot-melt extrusion. Read More
Mucosis, a Dutch clinical-stage biotechnology company, has signed a research and license option agreement with Crucell Holland, a Dutch developer of vaccines and antibodies. Read More
Oxford PharmaGenesis has opened a new facility in Switzerland. Read More
Penn Pharma underwent a successful FDA inspection at its Tredegar, United Kingdom facility. Read More
Sanofi and Massachusetts General Hospital have launched a collaboration aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors. Read More
Pharmanet/I3 has appointed Jamil Hantash as director of immunochemistry operations. Read More